SG Americas Securities LLC Sells 54,206 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

SG Americas Securities LLC lowered its stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 93.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,595 shares of the company's stock after selling 54,206 shares during the quarter. SG Americas Securities LLC's holdings in Revolution Medicines were worth $103,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of RVMD. MetLife Investment Management LLC increased its stake in Revolution Medicines by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 34,256 shares of the company's stock valued at $874,000 after purchasing an additional 12,643 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Revolution Medicines by 165.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 478,776 shares of the company's stock valued at $12,214,000 after purchasing an additional 298,436 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Revolution Medicines by 3.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 444,212 shares of the company's stock valued at $11,332,000 after purchasing an additional 13,134 shares in the last quarter. Northern Trust Corp increased its stake in Revolution Medicines by 12.3% during the 1st quarter. Northern Trust Corp now owns 629,849 shares of the company's stock valued at $16,067,000 after purchasing an additional 68,794 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Revolution Medicines by 3.2% in the 1st quarter. State Street Corp now owns 2,843,477 shares of the company's stock worth $72,537,000 after acquiring an additional 88,844 shares in the last quarter. Institutional investors own 94.34% of the company's stock.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 7,500 shares of the company's stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $35.48, for a total transaction of $266,100.00. Following the sale, the insider now directly owns 452,879 shares of the company's stock, valued at $16,068,146.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, General Counsel Jeff Cislini sold 1,500 shares of the stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $27.00, for a total value of $40,500.00. Following the sale, the general counsel now directly owns 36,126 shares of the company's stock, valued at $975,402. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mark A. Goldsmith sold 7,500 shares of the stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $35.48, for a total transaction of $266,100.00. Following the completion of the sale, the insider now directly owns 452,879 shares in the company, valued at $16,068,146.92. The disclosure for this sale can be found here. Insiders have sold a total of 20,205 shares of company stock valued at $671,249 over the last three months. 8.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Raymond James upgraded shares of Revolution Medicines from an "outperform" rating to a "strong-buy" rating and upped their target price for the stock from $36.00 to $48.00 in a research note on Wednesday, April 10th. Wedbush upped their target price on shares of Revolution Medicines from $41.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 27th. Oppenheimer upped their target price on shares of Revolution Medicines from $43.00 to $45.00 and gave the stock an "outperform" rating in a research note on Friday, April 12th. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 target price (up previously from $36.00) on shares of Revolution Medicines in a research note on Monday, April 8th. Finally, Piper Sandler initiated coverage on shares of Revolution Medicines in a research note on Monday, March 11th. They issued an "overweight" rating and a $43.00 target price for the company. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Revolution Medicines has a consensus rating of "Buy" and a consensus price target of $41.20.

Revolution Medicines Trading Down 2.5 %

Shares of NASDAQ:RVMD traded down $0.91 during midday trading on Friday, reaching $34.92. The company had a trading volume of 1,243,721 shares, compared to its average volume of 1,250,504. The stock has a market cap of $5.75 billion, a P/E ratio of -9.26 and a beta of 1.54. Revolution Medicines, Inc. has a 52-week low of $15.44 and a 52-week high of $38.73. The company's 50 day moving average price is $31.70 and its 200 day moving average price is $27.61.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Monday, February 26th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.29). The business had revenue of $0.74 million for the quarter, compared to analyst estimates of $1.20 million. The firm's revenue was down 95.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.63) earnings per share. Research analysts forecast that Revolution Medicines, Inc. will post -3.18 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.